pSivida (NSDQ:PSDV) touted results today from a second Phase III trial that the company conducted for its three-year posterior segment uveitis treatment.
The 153-patient study found that there was a significant reduction in the recurrence of posterior segment uveitis through 12 months in the group treated with pSivida’s drug-releasing ocular insert, Durasert.
Get the full story at our sister site, Drug Delivery Business News.
The post pSivida touts 12-month data from Ph3 trial of Durasert ocular insert appeared first on MassDevice.
from MassDevice http://ift.tt/2siT9sY
Cap comentari:
Publica un comentari a l'entrada